The aim of this review is to summarize the biological mechanisms described as causing the loss of CD19 antigen and subsequent leukemia escape after anti-CD19 CAR T therapy, as well as the available clinical data on CD19-negative ALL relapses. The gene discussed is CD19; the disease is leukemia.